Anzeige
Mehr »
Login
Donnerstag, 19.09.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Gold's geheime Rallye: Dieses Minenunternehmen wird 2025 durchstarten.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
327 Leser
Artikel bewerten:
(1)

Qrons Inc.: Qrons Announces U.S. Patent Office Grants Dartmouth College 3D Printing Patent Forming Basis of License Agreement with Qrons

NEW YORK, NY / ACCESSWIRE / April 22, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to report that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College which is directed to mechanically interlocked ,molecules-based materials for 3-D printing. The patents inventors are Professor Chenfeng Ke, a member of Qrons Scientific Advisory Board and Qianming Lin, Professor Ke's assistant.

Since July 2018, Qrons has conducted research with Professor Ke under a Sponsored Research Agreement with Dartmouth to develop innovative 3D printable hydrogels, biocompatible advanced materials as a component of its stem cell-based traumatic brain injury treatment. In October 2019, Qrons entered into an Intellectual Property License Agreement with Dartmouth for an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. This patent grant is the culmination of that process.

Professor Ke explained " I am really excited about the issuance of the patent. I think it is an important step forward for the development of our hydrogels. I think this issued patent, along with several pending patent applications forms the foundation of our technology. "

Jonah Meer, CEO of Qrons, commented " Ido Merfeld, our co-founder who worked closely with Dr. Ke, and I commend Professor Ke for his brilliance and diligence in obtaining this important patent. We are proud to have been part of the process and hope to engage in future projects with Professor Ke and his talented team at Dartmouth in furtherance of our development model that includes collaborating with leading academic institutions."

About Dartmouth College
Founded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.

About Qrons Inc.
Headquartered in New York City, with research conducted in Israel, Qrons is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases an enormous social and economic burden on society. Qrons' approach is to seek to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence , machine learning , molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. Our search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations. Please visit https://www.qrons.com.

Forward-Looking Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:
Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

SOURCE: Qrons Inc.



View source version on accesswire.com:
https://www.accesswire.com/641432/Qrons-Announces-US-Patent-Office-Grants-Dartmouth-College-3D-Printing-Patent-Forming-Basis-of-License-Agreement-with-Qrons

© 2021 ACCESSWIRE
Drei potenzielle Vervielfacher aus Osteuropa

In unserem kostenlosen Spezialreport nehmen wir Sie mit auf eine Reise durch die dynamischen und oft unterbewerteten Aktienmärkte Osteuropas. Die Region erlebt ein beeindruckendes Wirtschaftswachstum, das weit über den Erwartungen vieler Analysten liegt. Während westliche Märkte gesättigt erscheinen, bieten osteuropäische Unternehmen einzigartige Investitionsmöglichkeiten zu attraktiven Bewertungen.

Profitieren Sie vom Wachstum Osteuropas!

In dieser Ausgabe stellen wir Ihnen drei Top-Aktien vor, die nicht nur durch solide Fundamentaldaten glänzen, sondern auch durch ein enormes Wachstumspotenzial in den kommenden Jahren. Erfahren Sie, warum diese Favoriten bereit sind, die Märkte zu erobern und wie Sie als Investor von dieser Entwicklung profitieren können.

Verpassen Sie nicht die Chance, Teil dieser aufstrebenden Wirtschaft zu sein. Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, bei welchen unentdeckten Perlen noch enormes Potenzial schlummert.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.